拨康视云-B(02592)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02592 拨康视云-B

已收盘 07-23 16:08:04

1.350

+0.020

+1.50%

最高1.350	最低1.280	成交量3.95万
今开1.320	昨收1.330	日振幅5.26%
总市值11.92亿	流通市值11.92亿	总股本8.83亿
成交额5.15万	换手率0.00%	流通股本8.83亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02592","market":"HK","secType":"STK","nameCN":"拨康视云-B","latestPrice":1.35,"timestamp":1784794084402,"preClose":1.33,"halted":0,"volume":39500,"delay":0,"changeRate":0.015037593984962419,"floatShares":883000000,"shares":883000000,"eps":-0.103023,"marketStatus":"已收盘","change":0.02,"latestTime":"07-23 16:08:04","open":1.32,"high":1.35,"low":1.28,"amount":51535,"amplitude":0.052632,"askPrice":1.37,"askSize":45000,"bidPrice":1.29,"bidSize":2500,"shortable":0,"etf":0,"ttmEps":-0.598,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784856600000},"marketStatusCode":5,"adr":0,"listingDate":1751472000000,"exchange":"SEHK","adjPreClose":1.33,"openAndCloseTimeList":[[1784770200000,1784779200000],[1784782800000,1784793600000]],"volumeRatio":0.469679,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02592","defaultTab":"news","newsList":[{"id":"1131153726","title":"拨康视云-B（02592）：FDA完成CBT-358新药临床试验申请安全性审查","url":"https://stock-news.laohu8.com/highlight/detail?id=1131153726","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131153726?lang=zh_cn&edition=full","pubTime":"2026-07-17 18:47","pubTimestamp":1784285225,"startTime":"0","endTime":"0","summary":"7月17日，拨康视云-B发布自愿公告称，美国食品及药物管理局已于2026年7月14日完成对公司候选药物CBT-358新药临床试验申请的安全性审查，并对拟议开展的临床研究不持异议。该IND由公司于2026年5月21日向FDA递交。公司同时提醒，CBT-358及集团其他候选药物的最终开发、上市均存在不确定性；投资者在买卖公司股份时需审慎行事。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652407573","title":"拨康视云-B(02592.HK)：冯雅芳辞任公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2652407573","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652407573?lang=zh_cn&edition=full","pubTime":"2026-07-17 18:47","pubTimestamp":1784285221,"startTime":"0","endTime":"0","summary":"格隆汇7月17日丨拨康视云-B(02592.HK)宣布，冯雅芳已提交辞呈，辞任公司的公司秘书，且不再担任香港联合交易所有限公司证券上市规则第3.05条项下公司的授权代表及根据公司条例(香港法例第622章)公司于香港接收法律程序文件的授权代表，自2026年7月17日起生效。曾傲嫣已获委任为公司秘书及授权代表，自2026年7月17日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260717/32310890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","AVP","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652402056","title":"拨康视云-B(02592.HK)：美国药管局完成对CBT-358新药临床试验申请的安全性审查","url":"https://stock-news.laohu8.com/highlight/detail?id=2652402056","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652402056?lang=zh_cn&edition=full","pubTime":"2026-07-17 18:40","pubTimestamp":1784284833,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652140205","title":"拨康视云-B(02592)：美国药管局完成对CBT-358新药临床试验申请的安全性审查","url":"https://stock-news.laohu8.com/highlight/detail?id=2652140205","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652140205?lang=zh_cn&edition=full","pubTime":"2026-07-17 18:40","pubTimestamp":1784284833,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B 发布公告，于2026年7月14日，已完成有关于2026年5月21日向美国食品及药物管理局提交的CBT-358新药临床试验申请的审查期。美国药管局已完成对新药临床试验申请的安全性审查，并对拟议进行的临床研究不持异议。透过结合这两种成分，CBT-358有望治疗因泪液分泌不足所引起的干眼症，提升舒适度。本公司认为，由于美国药管局已完成对CBT-358的安全性审查，标志着CBT-358临床开发的关键里程碑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","CBT","02592","BMED","BK4090","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115807951","title":"拨康视云-B（02592）更换公司秘书及授权代表 曾傲嫣接任","url":"https://stock-news.laohu8.com/highlight/detail?id=1115807951","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115807951?lang=zh_cn&edition=full","pubTime":"2026-07-17 18:31","pubTimestamp":1784284270,"startTime":"0","endTime":"0","summary":"拨康视云-B7月17日公告称，董事会已收到馮雅芳女士的辞呈，其将自2026年7月17日起辞任公司秘书，并不再担任香港联合交易所证券上市规则第3.05条项下的授权代表及香港《公司条例》下的法律程序文件授权代表。馮女士确认与董事会无意见分歧，亦无其他事项需提请股东及联交所关注。曾女士拥有逾20年在监管合规、企业融资、公司秘书事务、内部控制、审计及财务管理等方面的经验。董事会对馮女士的贡献表示感谢，并欢迎曾女士的加入。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652402115","title":"拨康视云-B(02592.HK)：曾傲嫣获委任为公司秘书及授权代表","url":"https://stock-news.laohu8.com/highlight/detail?id=2652402115","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652402115?lang=zh_cn&edition=full","pubTime":"2026-07-17 18:29","pubTimestamp":1784284178,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173539052","title":"拨康视云-B6月股份变动月报：已发行股份增至880,467,081股","url":"https://stock-news.laohu8.com/highlight/detail?id=1173539052","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173539052?lang=zh_cn&edition=full","pubTime":"2026-07-06 14:39","pubTimestamp":1783319955,"startTime":"0","endTime":"0","summary":"拨康视云-B于2026年7月6日披露的最新股份变动月报表显示，公司截至2026年6月30日已发行股份总数从851,907,081股增至880,467,081股，增发28,560,000股普通股，无库藏股份产生。此次月报发布后，公司股本已于6月底增至880,467,081股。公司表示将继续严格遵守香港联交所《上市规则》及适用法律法规的要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648565288","title":"拨康视云-B(02592.HK)根据股份计划发行合共252.48万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648565288","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648565288?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:38","pubTimestamp":1783067938,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177805977","title":"拨康视云-B：7月3日增发252.48万股，已发行股本升至882,991,890股","url":"https://stock-news.laohu8.com/highlight/detail?id=1177805977","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177805977?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:37","pubTimestamp":1783067846,"startTime":"0","endTime":"0","summary":"拨康视云-B（股份代码：02592）于2026年7月3日发布翌日披露报表。根据公告，该公司在当日根据三项股权激励计划分别配发并发行1,104,000股、128,250股及1,292,559股普通股，合计增发2,524,809股，分别占前次已发行股本的0.13%、0.01%及0.15%。本次所增发股份每股发行价均为港币0元。  \n      \n本次增发完成后，截至2026年7月3日，公司已发行股本由880,467,081股增至882,991,890股，库藏股份保持为0股。公司确认，所有发行事项均已获董事会正式授权并遵守相关上市规则及适用法律法规。  \n      \n本公告由公司秘书冯雅芳签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"拨康视云-B：7月3日增发252.48万股，已发行股本升至882,991,890股","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186438215","title":"拨康视云-B于6月30日发行2,284.80万股 占已发行股本约2.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186438215","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186438215?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:46","pubTimestamp":1782809183,"startTime":"0","endTime":"0","summary":"拨康视云-B（股票代码：02592）于2026年6月30日发布翌日披露报表。公告显示，公司按照2023年股权激励计划，于当日向非董事之激励计划参与人配发并发行22,848,000股新股（约合2,284.80万股），占发行前公司已发行股本约2.66%。\n根据公告，此次发行的每股价格为0港元。发行完成后，公司已发行股份总数由857,619,081股增至880,467,081股，库藏股数量保持不变。\n公司确认，本次发行已获董事会正式授权批准，并已遵守包括香港联合交易所有限公司证券上市规则在内的所有适用法律和监管规定。公告由公司秘书冯雅芳签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"拨康视云-B于6月30日发行2,284.80万股 占已发行股本约2.66%","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647365275","title":"拨康视云-B(02592.HK)根据股权激励计划发行2284.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647365275","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647365275?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:42","pubTimestamp":1782808968,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645143010","title":"拨康视云-B拟向Abraham Dominguez Cinta发行认购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2645143010","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645143010?lang=zh_cn&edition=full","pubTime":"2026-06-22 08:28","pubTimestamp":1782088080,"startTime":"0","endTime":"0","summary":"　　拨康视云-B发布公告，于2026年6月18日，本公司与投资者ARC Group International Limited订立股份认购协议，本公司有权不时向投资者配发及发行股份，而投资者则须向本公司认购最多1500万美元的股份。投资者的最终实益拥有人为Abraham Dominguez Cinta先生。　　董事认为，股份认购协议乃参考市场状况及现行市场而厘定，并由本公司与投资者按公平基准及一般商业条款订立，且该协议的条款属公平合理，并符合本公司及股东的整体利益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-06-22/doc-iniefuxw9023038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644825140","title":"拨康视云-B(02592)拟向Abraham Dominguez Cinta发行认购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2644825140","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644825140?lang=zh_cn&edition=full","pubTime":"2026-06-18 23:04","pubTimestamp":1781795080,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B 发布公告，于2026年6月18日，本公司与投资者ARC Group International Limited订立股份认购协议，本公司有权不时向投资者配发及发行股份，而投资者则须向本公司认购最多1500万美元的股份。据悉，ARC Group International Limited是一间于香港注册成立的有限责任公司，为ARC Group Limited的直接全资附属公司。ARC Group Limited是一间深根于亚洲的全球金融服务及顾问公司，十多年来在投资银行、资产管理、财富管理及管理注询等领域表现卓越。投资者的最终实益拥有人为Abraham Dominguez Cinta先生。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456517.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1140712578","title":"拨康视云-B与ARC集团国际达成股份认购协议，融资额高达1500万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1140712578","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140712578?lang=zh_cn&edition=full","pubTime":"2026-06-18 22:52","pubTimestamp":1781794341,"startTime":"0","endTime":"0","summary":"拨康视云-B已与ARC集团国际签署一项股份认购协议，根据该协议，公司有望获得最高1500万美元的融资。此项交易旨在为公司的运营和发展提供资金支持，具体条款将依据协议规定执行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159102593","title":"拨康视云-B6月9日配发571.2万股新股 占已发行股本约0.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159102593","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159102593?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:42","pubTimestamp":1780994522,"startTime":"0","endTime":"0","summary":"拨康视云-B（股票代码：02592）于2026年6月9日发布公告称，公司根据2023年股权激励计划于当日配发并发行571.2万股普通股，占此前公司已发行股本（不含库藏股）约0.67%。\n公告显示，本次新股发行每股发行价为0港元。本次发行完成后，公司已发行股本由原先的851,907,081股增加至857,619,081股，库藏股数目维持为0股。\n公司于公告中确认，此次股票发行已获董事会正式授权并遵照相关上市规则及法律法规的规定进行。公告由公司秘书冯雅芳签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"拨康视云-B6月9日配发571.2万股新股 占已发行股本约0.67%","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642463848","title":"拨康视云-B(02592)根据股权激励计划发行571.2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642463848","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642463848?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:36","pubTimestamp":1780994200,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B(02592)发布公告，于2026年6月9日，根据2023年股权激励计划配发及发行571.2万股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138416578","title":"拨康视云宣布翼状胬肉潜在疗法CBT-001三期研究完成12个月疗效终点最终患者访视","url":"https://stock-news.laohu8.com/highlight/detail?id=1138416578","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138416578?lang=zh_cn&edition=full","pubTime":"2026-06-05 05:01","pubTimestamp":1780606896,"startTime":"0","endTime":"0","summary":"拨康视云（Cloudbreak Pharma）近日宣布，其针对翼状胬肉潜在治疗药物CBT-001开展的三期临床研究，已完成12个月疗效终点的最终患者访视。这一关键里程碑标志着该试验在评估长期治疗效果方面取得了实质性进展，为后续数据分析及监管申报奠定了重要基础。公司将持续推进研究进程，致力于为这一常见眼表疾病提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640864150","title":"拨康视云-B：核心产品CBT-001临床试验达重要里程碑，有望成全球首个翼状胬肉治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2640864150","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640864150?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:28","pubTimestamp":1780576080,"startTime":"0","endTime":"0","summary":"6月4日，拨康视云-B（02592）发布公告，其核心产品CBT-001的最后一名患者已完成为期12个月的终点访视，并于此次访视中进行了对CBT-001主要疗效终点（翼状胬肉病变缩小程度及眼部不适症状评分）在第3期多地区临床试验（“多地区临床试验”）中的评估。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760601811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK4090","CBT","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640161151","title":"拨康视云-B(02592)完成CBT-001最后一次为期12个月的终点访视","url":"https://stock-news.laohu8.com/highlight/detail?id=2640161151","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640161151?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:49","pubTimestamp":1780570172,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B 发布公告，最后一名患者已完成为期12个月的访视，并于此次访视中进行了对CBT-001主要疗效终点在第3期多地区临床试验中的评估。CBT-001为本集团核心产品之一。CBT-001又称尼达尼布游离硷，是一种局部眼用滴眼液乳液，目前正进行第3期多地区临床试验研究。本公司认为，完成最后一次为期12个月的终点访视是CBT-001开发过程中的重要里程碑，此举将使本公司得以在2026年第三季度公布12个月疗效的初步数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","CBT","02592","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113341406","title":"拨康视云-B 5月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1113341406","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113341406?lang=zh_cn&edition=full","pubTime":"2026-06-01 10:25","pubTimestamp":1780280745,"startTime":"0","endTime":"0","summary":"根据拨康视云-B于2026年6月1日提交的截至2026年5月31日的月报表显示，公司本期注册股本总额保持在2,000,000,000股普通股，面值为每股USD 0.0001，总额USD 200,000。已发行股份数量期初为851,907,081股，期末亦为851,907,081股，未发生新增发行、购回或注销。公司确认已遵守香港联交所《上市规则》及相关法律规定，所有股份及潜在股份的发行、回购及注销均得到了公司董事会正式批准。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://cloudbreakpharma.com","stockEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":0.1667},{"period":"3month","weight":-0.1635},{"period":"6month","weight":-0.4825},{"period":"1year","weight":-0.7663},{"period":"ytd","weight":-0.7442}],"compareEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":0.0473},{"period":"3month","weight":-0.0395},{"period":"6month","weight":-0.0694},{"period":"1year","weight":-0.0094},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"Cloudbreak Pharma Inc是一家临床阶段的眼科生物技术公司，从事开发各种治疗方法。该公司专注于眼科疗法的内部发现、开发和商业化。该公司拥有两款核心产品 CBT-001和CBT-009，均为自主研发。该公司的核心产品CBT-001用于治疗翼状胬肉（一种良性增生性眼表疾病），已在美国和中国启动III期多区域临床试验（MRCT）。该公司的核心产品CBT-009用于治疗青少年近视（5至19岁儿童和青少年的近视），已完成I/II期临床试验。该公司的其他候选药物处于相对早期的开发阶段，包括另外两种临床阶段候选药物，即CBT-006和CBT-004，以及四种临床前阶段候选药物，即CBT-007、CBT-199、CBT-145和CBT-011。","exchange":"SEHK","name":"拨康视云-B","nameEN":"CLOUDBREAK-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"拨康视云-B(02592)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供拨康视云-B(02592)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"拨康视云-B,02592,拨康视云-B股票,拨康视云-B股票老虎,拨康视云-B股票老虎国际,拨康视云-B行情,拨康视云-B股票行情,拨康视云-B股价,拨康视云-B股市,拨康视云-B股票价格,拨康视云-B股票交易,拨康视云-B股票购买,拨康视云-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"拨康视云-B(02592)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供拨康视云-B(02592)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}